文献速递消化道肿瘤与早癌消化内镜

靶向癌相关成纤维细胞分泌的WNT2可恢复树突状细胞介导的抗肿瘤免疫

Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.
PubMed 文献 · Gut · 2021-03-10

该研究在食管鳞癌和结直肠癌模型中探索癌相关成纤维细胞(CAF)介导免疫逃逸的机制。抗WNT2单抗可恢复瘤内抗肿瘤T细胞应答,并增强抗PD-1疗效;CAF分泌的WNT2通过SOCS3/p-JAK2/p-STAT3通路抑制树突状细胞分化及抗肿瘤T细胞应答。

要点

  • CAF分泌的WNT2抑制树突状细胞分化及抗肿瘤T细胞应答
  • 抗WNT2单抗可恢复瘤内抗肿瘤T细胞应答并增强抗PD-1疗效
  • WNT2通过SOCS3/p-JAK2/p-STAT3信号通路介导免疫抑制

核心结论

  • CAF可通过分泌WNT2抑制抗肿瘤免疫,靶向WNT2可能增强免疫检查点抑制剂疗效。

研究设计与样本

  • 使用抗WNT2单抗治疗荷mEC25或CMT93瘤的免疫健全C57BL/6小鼠,单用或联合抗PD-1,评估抗肿瘤效率与免疫应答。
  • 通过抗WNT2单抗或shRNA敲低CAF来源WNT2,分析CAF诱导的树突状细胞分化抑制及DC介导的抗肿瘤免疫。
  • 采用RNA测序和western blot探讨CAF诱导DC抑制的分子机制。

主要发现

  • 在原发食管鳞癌肿瘤中检测到WNT2+ CAF与活性CD8+ T细胞呈负相关。
  • 抗WNT2单抗显著恢复瘤内抗肿瘤T细胞应答,并通过增加活性DC增强抗PD-1在小鼠食管鳞癌和结直肠癌同系肿瘤模型中的疗效。
  • 直接干扰CAF来源WNT2可恢复DC分化和DC介导的抗肿瘤T细胞应答。
  • CAF分泌的WNT2通过SOCS3/p-JAK2/p-STAT3信号级联抑制DC介导的抗肿瘤T细胞应答。

临床怎么用

  • 靶向CAF分泌的WNT2可能作为增强免疫检查点抑制剂疗效的新策略,适用于食管鳞癌和结直肠癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Solid tumours respond poorly to immune checkpoint inhibitor (ICI) therapies. One major therapeutic obstacle is the immunosuppressive tumour microenvironment (TME). Cancer-associated fibroblasts (CAFs) are a key component of the TME and negatively regulate antitumour T-cell response. Here, we aimed to uncover the mechanism underlying CAFs-mediated tumour immune evasion and to develop novel therapeutic strategies targeting CAFs for enhancing ICI efficacy in oesophageal squamous cell carcinoma (OSCC) and colorectal cancer (CRC). DESIGN: Anti-WNT2 monoclonal antibody (mAb) was used to treat immunocompetent C57BL/6 mice bearing subcutaneously grafted mEC25 or CMT93 alone or combined with anti-programmed cell death protein 1 (PD-1), and the antitumour efficiency and immune response were assessed. CAFs-induced suppression of dendritic cell (DC)-differentiation and DC-mediated antitumour immunity were analysed by interfering with CAFs-derived WNT2, either by anti-WNT2 mAb or with short hairpin RNA-mediated knockdown. The molecular mechanism underlying CAFs-induced DC suppression was further explored by RNA-sequencing and western blot analyses. RESULTS: A negative correlation between WNT2+ CAFs and active CD8+ T cells was detected in primary OSCC tumours. Anti-WNT2 mAb significantly restored antitumour T-cell responses within tumours and enhanced the efficacy of anti-PD-1 by increasing active DC in both mouse OSCC and CRC syngeneic tumour models. Directly interfering with CAFs-derived WNT2 restored DC differentiation and DC-mediated antitumour T-cell responses. Mechanistic analyses further demonstrated that CAFs-secreted WNT2 suppresses the DC-mediated antitumour T-cell response via the SOCS3/p-JAK2/p-STAT3 signalling cascades. CONCLUSIONS: CAFs could suppress antitumour immunity through WNT2 secretion. Targeting WNT2 might enhance the ICI efficacy and represent a new anticancer immunotherapy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Huang TX, Tan XY, Huang HS, et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 2021. PMID: 33692094. doi:10.1136/gutjnl-2020-322924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。